Abstract:569 Background: Almost 50% of patients (pts) with aUC are ineligible for cisplatin-based chemotherapy, which is current first-line treatment. Cisplatin ineligibility is associated with worse outcomes, thus new promising treatment options are an unmet need. EV is an antibody drug conjugate, approved alone or in combination with Pembrolizumab for the treatment of pts with aUC. In the EV 201 study, cisplatin ineligible pts previously treated with checkpoint had a reported response rate (ORR) of 52% to EV alone. This real-world study aims to compare outcomes between cisplatin eligible and ineligible pts treated with EV monotherapy. Methods: This retrospective analysis of pts with aUC treated with EV monotherapy at Johns Hopkins compared investigator-assessed radiographic response to EV, progression free (PFS) and overall (OS) survival in cisplatin eligible vs ineligible pts. Cisplatin eligibility was determined by presence of ≥1 Galsky criteria: Eastern Cooperative Oncology Group Performance Status of ≥2, creatinine clearance < 60 mL/min, hearing loss ≥ Grade 2, neuropathy ≥ Grade 2 or New York Heart Association Class 3 heart failure. Patient demographics and treatment information were extracted by chart review. ORR [Complete Response (CR) + Partial Response (PR)] and Disease Control Rates (DCR) (CR + PR + Stable Disease) were compared between groups, using the χ 2 test. Multivariable Cox proportional hazard ratios adjusted for gender, race, presence of visceral metastasis and weight were used for comparing PFS and OS between groups, p < 0.05 was considered significant. Results: We identified 46 cisplatin eligible and 32 ineligible pts. The cisplatin eligible group had 36 (78.3%) white and 8 (17.4%) female pts vs 22 (68.8%) white and 12 (37.5%) females in the ineligible group. Mean age was 65.8 vs 76.3 years respectively. 16 (34.8%) cisplatin eligible pts and 12 (37.5%) cisplatin ineligible had upper tract UC. Among cisplatin eligible pts 38 (82.6%) had visceral metastasis at EV initiation vs 29 (90.6%) ineligible. Median PFS [95% Confidence Interval (95% CI)] was 5.7 months (3.8, 7.1) for cisplatin eligible pts and 3.9 (2.9, 5.5) for ineligible [Hazard Ratio (HR): 0.69, 95% CI: 0.41, 1.14, p=0.14]. Median OS (95% CI) was 9.7 (7.2, 12.0) months for cisplatin eligible pts vs 8.8 (5.8, N/A) for ineligible (HR: 0.90, 95%CI: 0.50, 1.62, p=0.7). ORR and DCR were 47.8% (34.1, 61.9) and 65.2% (50.8, 77.3) in cisplatin eligible pts vs 37.5% (22.9, 54.7) and 56.2% (39.3, 71.8) in ineligible pts (p= 0.37 and p=0.42 respectively). Conclusions: In this retrospective real-world study, there was no statistically significant difference in PFS, OS, ORR or DCR between cisplatin eligible and ineligible pts with aUC treated with EV. This is consistent with the excellent outcomes reported in the EV 201 study. Use of EV in aUC eliminates the artificial outcome gap defined by cisplatin eligibility.

Comparing survival in trial‐ versus routine‐care advanced urothelial cancer patients on immune checkpoint blockade

Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.

Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial

Trends over time in the proportion of sequential treatment and overall survival in patients with metastatic urothelial carcinoma in real-world practice.

Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort

A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy?

Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment

Real-world treatment patterns and outcomes of patients with unresectable or metastatic urothelial carcinoma receiving systemic therapy in Japan

Enfortumab vedotin (EV) in cisplatin-eligible and ineligible patients with advanced urothelial cancer (aUC): A single-center experience.

Four versus six cycles of platinum-based chemotherapy for advanced Urothelial carcinoma in the era of immune checkpoint inhibitors: A retrospective cohort study (FOCUS, KCSG-GU23-08)

A meta-analysis assessing objective response rates with first-line systemic treatment options in locally advanced/metastatic urothelial carcinoma.

Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort

Analysis of therapy attrition and changes in outcomes over time for patients (pts) with advanced urothelial cancer (aUC) treated at an academic center.

Efficacy and safety of the first-line systemic treatments in patients with advanced-stage urothelial carcinoma: a systematic review and network meta-analysis

Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

Impact of renal function eligibility criteria in clinical trials and real-world survival outcomes among patients with metastatic renal cell carcinoma.

Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy

Effectiveness and Safety of Immune Checkpoint Inhibitor Monotherapy in Advanced Upper Tract Urothelial Carcinoma: A Multicenter, Retrospective, Real‐world Study

Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options

Immunotherapy-Based Combinations in First-Line Urothelial Cancer: A Systematic Review and Individual Patient Data (IPD) Meta-Analysis

Real-world treatment (tx) patterns and clinical outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in Germany: Results of a retrospective observational study (CONVINCE).